ROTH Capital initiated coverage on Monopar Therapeutics with a new price target
$MNPR
Biotechnology: Pharmaceutical Preparations
Health Care
ROTH Capital initiated coverage of Monopar Therapeutics with a rating of Buy and set a new price target of $49.00